Gastric Cancer Diagnostic Market By Product (Reagents and Consumables, Instruments), By Disease Type (Adenocarcinoma, Gastric Lymphoma, Others), By End User (Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers): Global Opportunity Analysis and Industry Forecast, 2023-2032
The gastric cancer diagnostic market was valued at $2.3 billion in 2022 and is estimated to reach $3.8 million by 2032, exhibiting a CAGR of 5.3% from 2023 to 2032. Gastric cancer diagnostic refers to the process of identifying and confirming the presence of gastric (stomach) cancer in an individual. It involves various medical procedures and tests aimed at detecting and diagnosing this type of cancer. The goal of gastric cancer diagnostics is to determine if a person has malignant (cancerous) growth in the stomach, understand its characteristics, including the type and stage of the cancer, and provide valuable information to guide treatment decisions. Gastric cancer has become the second leading cause of cancer-related deaths worldwide, and its epidemiology has undergone significant changes in recent decades. During endoscopy or surgery, a tissue sample (biopsy) is collected from the suspicious area in the stomach. The biopsy is then examined by a pathologist to confirm the presence of cancer and determine its type and grade.
The gastric cancer diagnostic market has experienced significant growth owing to rise in prevalence of gastric cancer and advancements in diagnostics technology. For instance, according to the National Library of Medicine, a total of 1,089,103 new stomach cancer cases were reported globally for 2020. In addition, rise in awareness, screening programs about the importance of stomach cancer screening and the implementation of organized screening programs in some regions lead to early detection and diagnosis of gastric cancer, which fuels the market growth.
Furthermore, the rise in trend toward personalized or precision medicine fosters the use of molecular and genetic testing to identify specific genetic markers and tailor treatments to individual patients, boosting the demand for diagnostic tests and propelling the market growth. Furthermore, the ongoing advancements in diagnostic tools and technologies, such as improved endoscopy, molecular & genetic testing, and imaging techniques, enhance the accuracy and early detection of gastric cancer, which is expected to drive the market growth.
The gastric cancer diagnostic market is segmented into product, disease type, end user, and region. By product, the market is segregated into reagents & consumables and instruments. By disease type, the market is categorized into adenocarcinoma, gastric lymphoma, and others. By end user, the market is classified into hospitals, diagnostic laboratories, and diagnostic imaging centers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).
Major key players that operate in the gastric cancer diagnostic market are Bio-Rad Laboratories, Inc., Qiagen NV., Agilent Technologies, Inc., Exact Sciences Corporation, MiRXES Pte Ltd, Hipro Biotechnology Co.,Ltd., Fulgent Genetics, Endofotonics Pte Ltd, Abbott Laboratories, and F. Hoffmann-La Roche Ltd. Key players have adopted product approval, partnership, and agreement as key developmental strategies to improve the product portfolio of the gastric cancer diagnostic market.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gastric cancer diagnostic market analysis from 2022 to 2032 to identify the prevailing gastric cancer diagnostic market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the gastric cancer diagnostic market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global gastric cancer diagnostic market trends, key players, market segments, application areas, and market growth strategies.
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Product
Reagents and Consumables
Instruments
By Disease Type
Adenocarcinoma
Gastric Lymphoma
Others
By End User
Hospitals
Diagnostic Laboratories
Diagnostic Imaging Centers
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Exact Sciences Corporation
Fulgent Genetics
Endofotonics Pte Ltd
MiRXES Pte Ltd
F. Hoffmann-La Roche Ltd.
Agilent Technologies, Inc.
Hipro Biotechnology Co.,Ltd.
Abbott Laboratories
Qiagen NV.
Bio-Rad Laboratories, Inc.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Increase in incidence of gastric cancer
- 3.4.1.2. Advancements in diagnostic technologies
- 3.4.1.3. Growing awareness about gastric cancer
- 3.4.2. Restraints
- 3.4.2.1. High diagnostic cost
- 3.4.3. Opportunities
- 3.4.3.1. Significant unmet need in cancer diagnosis
- 3.4.3.2. Growth opportunities in emerging markets
- CHAPTER 4: GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Reagents and Consumables
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Instruments
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- CHAPTER 5: GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Adenocarcinoma
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Gastric Lymphoma
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- 5.4. Others
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
- CHAPTER 6: GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Hospitals
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Diagnostic Laboratories
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Diagnostic Imaging Centers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- CHAPTER 7: GASTRIC CANCER DIAGNOSTIC MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Product
- 7.2.3. Market size and forecast, by Disease Type
- 7.2.4. Market size and forecast, by End User
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Market size and forecast, by Product
- 7.2.5.1.2. Market size and forecast, by Disease Type
- 7.2.5.1.3. Market size and forecast, by End User
- 7.2.5.2. Canada
- 7.2.5.2.1. Market size and forecast, by Product
- 7.2.5.2.2. Market size and forecast, by Disease Type
- 7.2.5.2.3. Market size and forecast, by End User
- 7.2.5.3. Mexico
- 7.2.5.3.1. Market size and forecast, by Product
- 7.2.5.3.2. Market size and forecast, by Disease Type
- 7.2.5.3.3. Market size and forecast, by End User
- 7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Product
- 7.3.3. Market size and forecast, by Disease Type
- 7.3.4. Market size and forecast, by End User
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Market size and forecast, by Product
- 7.3.5.1.2. Market size and forecast, by Disease Type
- 7.3.5.1.3. Market size and forecast, by End User
- 7.3.5.2. France
- 7.3.5.2.1. Market size and forecast, by Product
- 7.3.5.2.2. Market size and forecast, by Disease Type
- 7.3.5.2.3. Market size and forecast, by End User
- 7.3.5.3. UK
- 7.3.5.3.1. Market size and forecast, by Product
- 7.3.5.3.2. Market size and forecast, by Disease Type
- 7.3.5.3.3. Market size and forecast, by End User
- 7.3.5.4. Italy
- 7.3.5.4.1. Market size and forecast, by Product
- 7.3.5.4.2. Market size and forecast, by Disease Type
- 7.3.5.4.3. Market size and forecast, by End User
- 7.3.5.5. Spain
- 7.3.5.5.1. Market size and forecast, by Product
- 7.3.5.5.2. Market size and forecast, by Disease Type
- 7.3.5.5.3. Market size and forecast, by End User
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Market size and forecast, by Product
- 7.3.5.6.2. Market size and forecast, by Disease Type
- 7.3.5.6.3. Market size and forecast, by End User
- 7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Product
- 7.4.3. Market size and forecast, by Disease Type
- 7.4.4. Market size and forecast, by End User
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Market size and forecast, by Product
- 7.4.5.1.2. Market size and forecast, by Disease Type
- 7.4.5.1.3. Market size and forecast, by End User
- 7.4.5.2. China
- 7.4.5.2.1. Market size and forecast, by Product
- 7.4.5.2.2. Market size and forecast, by Disease Type
- 7.4.5.2.3. Market size and forecast, by End User
- 7.4.5.3. India
- 7.4.5.3.1. Market size and forecast, by Product
- 7.4.5.3.2. Market size and forecast, by Disease Type
- 7.4.5.3.3. Market size and forecast, by End User
- 7.4.5.4. Australia
- 7.4.5.4.1. Market size and forecast, by Product
- 7.4.5.4.2. Market size and forecast, by Disease Type
- 7.4.5.4.3. Market size and forecast, by End User
- 7.4.5.5. South Korea
- 7.4.5.5.1. Market size and forecast, by Product
- 7.4.5.5.2. Market size and forecast, by Disease Type
- 7.4.5.5.3. Market size and forecast, by End User
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Market size and forecast, by Product
- 7.4.5.6.2. Market size and forecast, by Disease Type
- 7.4.5.6.3. Market size and forecast, by End User
- 7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Product
- 7.5.3. Market size and forecast, by Disease Type
- 7.5.4. Market size and forecast, by End User
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Market size and forecast, by Product
- 7.5.5.1.2. Market size and forecast, by Disease Type
- 7.5.5.1.3. Market size and forecast, by End User
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Market size and forecast, by Product
- 7.5.5.2.2. Market size and forecast, by Disease Type
- 7.5.5.2.3. Market size and forecast, by End User
- 7.5.5.3. South Africa
- 7.5.5.3.1. Market size and forecast, by Product
- 7.5.5.3.2. Market size and forecast, by Disease Type
- 7.5.5.3.3. Market size and forecast, by End User
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Market size and forecast, by Product
- 7.5.5.4.2. Market size and forecast, by Disease Type
- 7.5.5.4.3. Market size and forecast, by End User
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product mapping of top 10 player
- 8.4. Competitive dashboard
- 8.5. Competitive heatmap
- 8.6. Top player positioning, 2022
- CHAPTER 9: COMPANY PROFILES
- 9.1. Bio-Rad Laboratories, Inc.
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.2. Qiagen NV.
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
- 9.3. Agilent Technologies, Inc.
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
- 9.4. MiRXES Pte Ltd
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Key strategic moves and developments
- 9.5. Hipro Biotechnology Co.,Ltd.
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.6. Fulgent Genetics
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.7. Exact Sciences Corporation
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
- 9.8. Endofotonics Pte Ltd
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.9. Abbott Laboratories
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.10. F. Hoffmann-La Roche Ltd.
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- LIST OF TABLES
- TABLE 01. GLOBAL GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 02. GASTRIC CANCER DIAGNOSTIC MARKET FOR REAGENTS AND CONSUMABLES, BY REGION, 2022-2032 ($MILLION)
- TABLE 03. GASTRIC CANCER DIAGNOSTIC MARKET FOR INSTRUMENTS, BY REGION, 2022-2032 ($MILLION)
- TABLE 04. GLOBAL GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 05. GASTRIC CANCER DIAGNOSTIC MARKET FOR ADENOCARCINOMA, BY REGION, 2022-2032 ($MILLION)
- TABLE 06. GASTRIC CANCER DIAGNOSTIC MARKET FOR GASTRIC LYMPHOMA, BY REGION, 2022-2032 ($MILLION)
- TABLE 07. GASTRIC CANCER DIAGNOSTIC MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 08. GLOBAL GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 09. GASTRIC CANCER DIAGNOSTIC MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
- TABLE 10. GASTRIC CANCER DIAGNOSTIC MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2032 ($MILLION)
- TABLE 11. GASTRIC CANCER DIAGNOSTIC MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 12. GASTRIC CANCER DIAGNOSTIC MARKET, BY REGION, 2022-2032 ($MILLION)
- TABLE 13. NORTH AMERICA GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 14. NORTH AMERICA GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 15. NORTH AMERICA GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 16. NORTH AMERICA GASTRIC CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 17. U.S. GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 18. U.S. GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 19. U.S. GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 20. CANADA GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 21. CANADA GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 22. CANADA GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 23. MEXICO GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 24. MEXICO GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 25. MEXICO GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 26. EUROPE GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 27. EUROPE GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 28. EUROPE GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 29. EUROPE GASTRIC CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 30. GERMANY GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 31. GERMANY GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 32. GERMANY GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 33. FRANCE GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 34. FRANCE GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 35. FRANCE GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 36. UK GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 37. UK GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 38. UK GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 39. ITALY GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 40. ITALY GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 41. ITALY GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 42. SPAIN GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 43. SPAIN GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 44. SPAIN GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 45. REST OF EUROPE GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 46. REST OF EUROPE GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 47. REST OF EUROPE GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 48. ASIA-PACIFIC GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 49. ASIA-PACIFIC GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 50. ASIA-PACIFIC GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 51. ASIA-PACIFIC GASTRIC CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 52. JAPAN GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 53. JAPAN GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 54. JAPAN GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 55. CHINA GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 56. CHINA GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 57. CHINA GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 58. INDIA GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 59. INDIA GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 60. INDIA GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 61. AUSTRALIA GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 62. AUSTRALIA GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 63. AUSTRALIA GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 64. SOUTH KOREA GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 65. SOUTH KOREA GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 66. SOUTH KOREA GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 67. REST OF ASIA-PACIFIC GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 68. REST OF ASIA-PACIFIC GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 69. REST OF ASIA-PACIFIC GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 70. LAMEA GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 71. LAMEA GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 72. LAMEA GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 73. LAMEA GASTRIC CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 74. BRAZIL GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 75. BRAZIL GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 76. BRAZIL GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 77. SAUDI ARABIA GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 78. SAUDI ARABIA GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 79. SAUDI ARABIA GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 80. SOUTH AFRICA GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 81. SOUTH AFRICA GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 82. SOUTH AFRICA GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 83. REST OF LAMEA GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 84. REST OF LAMEA GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
- TABLE 85. REST OF LAMEA GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 86. BIO-RAD LABORATORIES, INC. : KEY EXECUTIVES
- TABLE 87. BIO-RAD LABORATORIES, INC. : COMPANY SNAPSHOT
- TABLE 88. BIO-RAD LABORATORIES, INC. : PRODUCT SEGMENTS
- TABLE 89. BIO-RAD LABORATORIES, INC. : PRODUCT PORTFOLIO
- TABLE 90. QIAGEN NV.: KEY EXECUTIVES
- TABLE 91. QIAGEN NV.: COMPANY SNAPSHOT
- TABLE 92. QIAGEN NV.: PRODUCT SEGMENTS
- TABLE 93. QIAGEN NV.: PRODUCT PORTFOLIO
- TABLE 94. QIAGEN NV.: KEY STRATERGIES
- TABLE 95. AGILENT TECHNOLOGIES, INC.: KEY EXECUTIVES
- TABLE 96. AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
- TABLE 97. AGILENT TECHNOLOGIES, INC.: PRODUCT SEGMENTS
- TABLE 98. AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
- TABLE 99. AGILENT TECHNOLOGIES, INC.: KEY STRATERGIES
- TABLE 100. MIRXES PTE LTD: KEY EXECUTIVES
- TABLE 101. MIRXES PTE LTD: COMPANY SNAPSHOT
- TABLE 102. MIRXES PTE LTD: PRODUCT SEGMENTS
- TABLE 103. MIRXES PTE LTD: PRODUCT PORTFOLIO
- TABLE 104. MIRXES PTE LTD: KEY STRATERGIES
- TABLE 105. HIPRO BIOTECHNOLOGY CO.,LTD.: KEY EXECUTIVES
- TABLE 106. HIPRO BIOTECHNOLOGY CO.,LTD.: COMPANY SNAPSHOT
- TABLE 107. HIPRO BIOTECHNOLOGY CO.,LTD.: PRODUCT SEGMENTS
- TABLE 108. HIPRO BIOTECHNOLOGY CO.,LTD.: PRODUCT PORTFOLIO
- TABLE 109. FULGENT GENETICS: KEY EXECUTIVES
- TABLE 110. FULGENT GENETICS: COMPANY SNAPSHOT
- TABLE 111. FULGENT GENETICS: PRODUCT SEGMENTS
- TABLE 112. FULGENT GENETICS: PRODUCT PORTFOLIO
- TABLE 113. EXACT SCIENCES CORPORATION: KEY EXECUTIVES
- TABLE 114. EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT
- TABLE 115. EXACT SCIENCES CORPORATION: PRODUCT SEGMENTS
- TABLE 116. EXACT SCIENCES CORPORATION: PRODUCT PORTFOLIO
- TABLE 117. EXACT SCIENCES CORPORATION: KEY STRATERGIES
- TABLE 118. ENDOFOTONICS PTE LTD: KEY EXECUTIVES
- TABLE 119. ENDOFOTONICS PTE LTD: COMPANY SNAPSHOT
- TABLE 120. ENDOFOTONICS PTE LTD: PRODUCT SEGMENTS
- TABLE 121. ENDOFOTONICS PTE LTD: PRODUCT PORTFOLIO
- TABLE 122. ABBOTT LABORATORIES: KEY EXECUTIVES
- TABLE 123. ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 124. ABBOTT LABORATORIES: PRODUCT SEGMENTS
- TABLE 125. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 126. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
- TABLE 127. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
- TABLE 128. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
- TABLE 129. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
- LIST OF FIGURES
- FIGURE 01. GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF GASTRIC CANCER DIAGNOSTIC MARKET,2022-2032
- FIGURE 03. TOP IMPACTING FACTORS IN GASTRIC CANCER DIAGNOSTIC MARKET (2022 TO 2032)
- FIGURE 04. TOP INVESTMENT POCKETS IN GASTRIC CANCER DIAGNOSTIC MARKET (2023-2032)
- FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 07. MODERATE THREAT OF SUBSTITUTES
- FIGURE 08. MODERATE INTENSITY OF RIVALRY
- FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 10. GLOBAL GASTRIC CANCER DIAGNOSTIC MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 11. GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022 AND 2032(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER DIAGNOSTIC MARKET FOR REAGENTS AND CONSUMABLES, BY COUNTRY 2022 AND 2032(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER DIAGNOSTIC MARKET FOR INSTRUMENTS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 14. GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022 AND 2032(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER DIAGNOSTIC MARKET FOR ADENOCARCINOMA, BY COUNTRY 2022 AND 2032(%)
- FIGURE 16. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER DIAGNOSTIC MARKET FOR GASTRIC LYMPHOMA, BY COUNTRY 2022 AND 2032(%)
- FIGURE 17. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER DIAGNOSTIC MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 18. GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022 AND 2032(%)
- FIGURE 19. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER DIAGNOSTIC MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 20. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER DIAGNOSTIC MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY 2022 AND 2032(%)
- FIGURE 21. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER DIAGNOSTIC MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 22. GASTRIC CANCER DIAGNOSTIC MARKET BY REGION, 2022 AND 2032(%)
- FIGURE 23. U.S. GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
- FIGURE 24. CANADA GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
- FIGURE 25. MEXICO GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
- FIGURE 26. GERMANY GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
- FIGURE 27. FRANCE GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
- FIGURE 28. UK GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
- FIGURE 29. ITALY GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
- FIGURE 30. SPAIN GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
- FIGURE 31. REST OF EUROPE GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
- FIGURE 32. JAPAN GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
- FIGURE 33. CHINA GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
- FIGURE 34. INDIA GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
- FIGURE 35. AUSTRALIA GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
- FIGURE 36. SOUTH KOREA GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
- FIGURE 37. REST OF ASIA-PACIFIC GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
- FIGURE 38. BRAZIL GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
- FIGURE 39. SAUDI ARABIA GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
- FIGURE 40. SOUTH AFRICA GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
- FIGURE 41. REST OF LAMEA GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
- FIGURE 42. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 43. COMPETITIVE DASHBOARD
- FIGURE 44. COMPETITIVE HEATMAP: GASTRIC CANCER DIAGNOSTIC MARKET
- FIGURE 45. TOP PLAYER POSITIONING, 2022
- FIGURE 46. BIO-RAD LABORATORIES, INC. : NET SALES, 2020-2022 ($MILLION)
- FIGURE 47. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 48. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 49. QIAGEN NV.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 50. QIAGEN NV.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 51. QIAGEN NV.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 52. AGILENT TECHNOLOGIES, INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 53. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 54. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 55. EXACT SCIENCES CORPORATION: NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 56. EXACT SCIENCES CORPORATION: REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 57. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
- FIGURE 58. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 59. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 60. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
- FIGURE 61. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook